2VSA.F Verastem, Inc.

Healthcare Biotechnology Frankfurt Exchange
7.46 EUR
Close of Nov 11, 2026
2.88 9.15
Market cap
EUR 940M
P/E
-
P/B
101.04x
ROE
-1,927.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 2VSA.F undervalued?

Graham number

The Graham number of Verastem, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Verastem, Inc. fundamental analysis

No fundamental analysis for Verastem, Inc. yet.

Verastem, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Verastem, Inc.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactini…

Full company profile